External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ASNR 2023

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Personalised Healthcare
Apr 29 / Roche and Genentech
GRADUATE I and II: Imaging Findings From Two Phase III trials of Subcutaneous Gantenerumab in Early Alzheimer’s Disease
The GRADUATE I and II studies assessing the efficacy and safety of gantenerumab in early AD included amyloid and tau PET substudies and volumetric magnetic resonance imaging measures to investigate the effects of gantenerumab treatment on these imaging biomarkers in participants. These findings provide further insights into the effects of subcutaneous gantenerumab on amyloid and tau load, and regional brain volume in early AD.

Sign up or login to unlock the full suite of MEDICALLY features

Personalised Healthcare
Apr 29 / Roche and Genentech
Baseline risk factors for developing ARIA-E from the SCarlet RoAD and Marguerite RoAD open-label extension studies
Data from the SCarlet RoAD and Marguerite RoAD open-label extensions were used to identify potential baseline risk factors for the occurrence of ARIA-E under gantenerumab treatment. APOE ε4 carrier status, in particular homozygous status, and microhemorrhage presence were identified as independent, nonmodifiable, and cumulative baseline risk factors for ARIA-E.